FierceBiotechOriginal article
{"a":[{"_":"Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trial","$":{"href":"/biotech/ateas-hepatitis-c-asset-matches-gileads-epclusa-phase-3-trial","hreflang":"en"}}]}
Phase 3positiveAtea hepatitis C assetEpclusaPositive
AI Analysis
Summary
Atea Pharmaceuticals' investigational hepatitis C treatment demonstrated efficacy matching Gilead's established Epclusa in a phase 3 trial, supporting the company's advancement toward a second readout for its shorter treatment regimen.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Atea's hepatitis C prospect matched Gilead's Epclusa in phase 3 trial
Importance:7/10
Sentiment:
0.65
hepatitis Cphase 3clinical trialdrug developmentcompetitive comparison
Related Companies
Read the original article
Published by FierceBiotech on July 28, 2026 9:09 AM